BRAF and metastatic neoplasm: Among patients treated for metastatic disease, in the univariate analysis, OSICI was not affected by factors such as age, sex, race, pre-treatment lactate dehydrogenase level, or BRAF status; thus, no multivariate analysis was conducted.